While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to ...

InflaRx presented data analyses from a terminated Phase 3 study on the potential treatment for rare skin condition.

InflaRx (IFRX) outlined multiple data analyses of the Phase 3 study for vilobelimab in pyoderma gangrenosum, which was terminated earlier this ...

While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to futility regarding its prespecified primary endpoint (as previously disclosed), ...